Acquisition by Nikolay Savchuk of 885532 shares of Traws Pharma at 0.01 subject to Rule 16b-3
| TRAW Stock | 7.17 0.00 0.00% |
Slightly above 57% of all Traws Pharma's sophisticated investors are looking to take a long position. The analysis of overall sentiment of trading Traws Pharma stock suggests that some investors are interested at this time. Traws Pharma's investing sentiment can be driven by a variety of factors including economic data, Traws Pharma's earnings reports, geopolitical events, and overall market trends.
Traws |
Filed transaction by Traws Pharma Director, Officer Chief Operating Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Traws Pharma's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Traws Pharma's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Traws Pharma Fundamental Analysis
We analyze Traws Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Traws Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Traws Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Traws Pharma is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Traws Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Traws Pharma stock to make a market-neutral strategy. Peer analysis of Traws Pharma could also be used in its relative valuation, which is a method of valuing Traws Pharma by comparing valuation metrics with similar companies.
Peers
Traws Pharma Related Equities
| BOOT | Boot Barn | 0.00 |
| ||
| RCKY | Rocky Brands | 0.00 |
| ||
| SUM | Summit Materials | 0.23 |
| ||
| PMNXF | Perseus Mining | 2.78 |
| ||
| SKX | Skechers USA | 3.51 |
| ||
| KTB | Kontoor Brands | 3.87 |
|
Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.